Zebra Capital Management LLC lowered its stake in Luminex Co. (NASDAQ:LMNX) by 38.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,880 shares of the medical instruments supplier’s stock after selling 16,681 shares during the quarter. Zebra Capital Management LLC owned about 0.06% of Luminex worth $794,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. PEAK6 Investments L.P. acquired a new stake in shares of Luminex in the second quarter valued at about $359,000. Cubist Systematic Strategies LLC grew its stake in shares of Luminex by 7,572.6% in the second quarter. Cubist Systematic Strategies LLC now owns 7,289 shares of the medical instruments supplier’s stock valued at $215,000 after buying an additional 7,194 shares in the last quarter. OppenheimerFunds Inc. acquired a new stake in shares of Luminex in the second quarter valued at about $231,000. BlueMountain Capital Management LLC grew its stake in shares of Luminex by 68.9% in the second quarter. BlueMountain Capital Management LLC now owns 17,414 shares of the medical instruments supplier’s stock valued at $514,000 after buying an additional 7,104 shares in the last quarter. Finally, Citadel Advisors LLC grew its stake in shares of Luminex by 32.6% in the second quarter. Citadel Advisors LLC now owns 244,416 shares of the medical instruments supplier’s stock valued at $7,217,000 after buying an additional 60,041 shares in the last quarter. Institutional investors and hedge funds own 82.23% of the company’s stock.

Shares of NASDAQ LMNX opened at $29.78 on Friday. Luminex Co. has a fifty-two week low of $18.62 and a fifty-two week high of $35.37. The company has a market cap of $1.31 billion, a price-to-earnings ratio of 32.73, a price-to-earnings-growth ratio of 3.39 and a beta of 0.24.

Luminex (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, August 6th. The medical instruments supplier reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.04). Luminex had a net margin of 10.57% and a return on equity of 7.44%. The business had revenue of $79.60 million for the quarter, compared to analyst estimates of $79.66 million. During the same quarter last year, the business earned $0.26 EPS. Luminex’s revenue for the quarter was up 4.1% compared to the same quarter last year. equities research analysts forecast that Luminex Co. will post 0.58 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 12th. Shareholders of record on Friday, September 21st will be paid a dividend of $0.06 per share. The ex-dividend date is Thursday, September 20th. This represents a $0.24 dividend on an annualized basis and a yield of 0.81%. Luminex’s dividend payout ratio (DPR) is presently 26.37%.

In other Luminex news, Director G Walter Loewenbaum II sold 3,203 shares of the firm’s stock in a transaction that occurred on Wednesday, June 20th. The stock was sold at an average price of $30.91, for a total transaction of $99,004.73. Following the completion of the sale, the director now owns 531,948 shares in the company, valued at approximately $16,442,512.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.40% of the stock is owned by company insiders.

A number of equities research analysts have recently issued reports on the company. ValuEngine upgraded Luminex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 19th. Jefferies Financial Group restated a “hold” rating and set a $27.00 price objective on shares of Luminex in a research note on Tuesday, August 7th. Zacks Investment Research upgraded Luminex from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research note on Monday, July 9th. BidaskClub upgraded Luminex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 24th. Finally, Citigroup raised their price objective on Luminex from $23.00 to $34.00 and gave the company a “$33.58” rating in a research note on Monday, July 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $28.60.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

See Also: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.